Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders

Psychopharmacology: The third generation of progress

O'Connell, R. A. (1988) · Comprehensive Psychiatry · doi:10.1016/0010-440x(88)90057-0 · Cited by 3,013

Psychopharmacology: The Third Generation of Progress.

(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-509_2 · Cited by 2,014

Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study

Swanson, L. W., Sawchenko, P. E., Rivier, J., & Vale, W. W. (2008) · Neuroendocrinology · doi:10.1159/000123454 · Cited by 1,953

Allostasis and Allostatic Load Implications for Neuropsychopharmacology

McEwen, B. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00129-3 · Cited by 1,833

The neurobiology of attachment

Insel, T. R., & Young, L. J. (2001) · Nature Reviews Neuroscience · doi:10.1038/35053579 · Cited by 1,173

Distinct Mechanism for Antidepressant Activity by Blockade of Central Substance P Receptors

Kramer, M. S., Cutler, N., Feighner, J., Shrivastava, R., Carman, J., Sramek, J. J., Reines, S. A., Liu, G., Snavely, D., Wyatt-Knowles, E., et al. (1998) · Science · doi:10.1126/science.281.5383.1640 · Cited by 1,071

Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1

Timpl, P., Spanagel, R., Sillaber, I., Kresse, A., Reul, J. M. H. M., Stalla, G. K., Blanquet, V., Steckler, T., Holsboer, F., & Wurst, W. (1998) · Nature Genetics · doi:10.1038/520 · Cited by 919

Antidepressants and Hypothalamic-Pituitary-Adrenocortical Regulation

HOLSBOER, F., & BARDEN, N. (1996) · Endocrine Reviews · doi:10.1210/edrv-17-2-187 · Cited by 852

Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress

Bale, T. L., Contarino, A., Smith, G. W., Chan, R., Gold, L. H., Sawchenko, P. E., Koob, G. F., Vale, W. W., & Lee, K.-F. (2000) · Nature Genetics · doi:10.1038/74263 · Cited by 849

Altered nociception, analgesia and aggression in mice lacking the receptor for substance P

Felipe, C. D., Herrero, J. F., O'Brien, J. A., Palmer, J. A., Doyle, C. A., Smith, A. J. H., Laird, J. M. A., Belmonte, C., Cervero, F., & Hunt, S. P. (1998) · Nature · doi:10.1038/32904 · Cited by 755

Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated

Zobel, A. W., Nickel, T., Künzel, H. E., Ackl, N., Sonntag, A., Ising, M., & Holsboer, F. (2000) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(00)00016-9 · Cited by 705

Neuropeptides — an overview

Hökfelt, T., Broberger, C., Xu, Z.-Q. D., Sergeyev, V., Ubink, R., & Diez, M. (2000) · Neuropharmacology · doi:10.1016/s0028-3908(00)00010-1 · Cited by 604

Coexistence of peptides and classical neurotransmitters

Lundberg, J. M., & Hökfelt, T. (1983) · Trends in Neurosciences · doi:10.1016/0166-2236(83)90149-2 · Cited by 561

Galanin receptor subtypes

Branchek, T. A., Smith, K. E., Gerald, C., & Walker, M. W. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01446-2 · Cited by 496

Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V 1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders

Griebel, G., Simiand, J., Serradeil-Le Gal, C., Wagnon, J., Pascal, M., Scatton, B., Maffrand, J.-P., & Soubrié, P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092012099 · Cited by 471

Neuropeptide Y: emerging evidence for a functional role in seizure modulation

Vezzani, A., Sperk, G., & Colmers, W. F. (1999) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01284-3 · Cited by 469

Ethanol consumption and resistance are inversely related to neuropeptide Y levels

Thiele, T. E., Marsh, D. J., Ste. Marie, L., Bernstein, I. L., & Palmiter, R. D. (1998) · Nature · doi:10.1038/24614 · Cited by 468

Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates

Habib, K. E., Weld, K. P., Rice, K. C., Pushkas, J., Champoux, M., Listwak, S., Webster, E. L., Atkinson, A. J., Schulkin, J., Contoreggi, C., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.11.6079 · Cited by 403

Vasopressin V1b receptor knockout reduces aggressive behavior in male mice

Wersinger, S. R., Ginns, E. I., O'Carroll, A.-M., Lolait, S. J., & Young III, W. S. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001195 · Cited by 397

Vasopressinergic regulation of the hypothalamic–pituitary–adrenal axis: implications for stress adaptation

Aguilera, G., & Rabadan-Diehl, C. (2000) · Regulatory Peptides · doi:10.1016/s0167-0115(00)00196-8 · Cited by 375

The neurocircuitry and receptor subtypes mediating anxiolytic-like effects of neuropeptide Y

Kask, A., Harro, J., von Hörsten, S., Redrobe, J. P., Dumont, Y., & Quirion, R. (2002) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(01)00066-5 · Cited by 358

Anxiolytic-Like Action of Neuropeptide Y: Mediation by Y1 Receptors in Amygdala, and Dissociation from Food Intake Effects

Heilig, M., McLeod, S., Brot, M., Heinrichs, S. C., Menzaghi, F., Koob, G. F., & Britton, K. T. (1993) · Neuropsychopharmacology · doi:10.1038/npp.1993.35 · Cited by 356

Extrapituitary expression of the rat V1b vasopressin receptor gene.

Lolait, S. J., O'Carroll, A. M., Mahan, L. C., Felder, C. C., Button, D. C., Young, W. S., Mezey, E., & Brownstein, M. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.6783 · Cited by 337

Corticotropin-releasing hormone receptor subtypes and emotion

Steckler, T., & Holsboer, F. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00170-5 · Cited by 326

Corticotropin-releasing factor and neuropeptide y: role in emotional integration

Heilig, M., Koob, G. F., Ekman, R., & Britton, K. T. (1994) · Trends in Neurosciences · doi:10.1016/0166-2236(94)90079-5 · Cited by 324

Behavioral insensitivity to restraint stress, absent fear suppression of behavior and impaired spatial learning in transgenic rats with hippocampal neuropeptide Y overexpression

Thorsell, A., Michalkiewicz, M., Dumont, Y., Quirion, R., Caberlotto, L., Rimondini, R., Mathé, A. A., & Heilig, M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.220232997 · Cited by 315

Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function

Santarelli, L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.041596398 · Cited by 303

Vasopressin cells in the medial amygdala of the rat project to the lateral septum and ventral hippocampus

Caffé, A. R., van Leeuwen, F. W., & Luiten, P. G. M. (1987) · Journal of Comparative Neurology · doi:10.1002/cne.902610206 · Cited by 286

Demonstration of the Efficacy and Safety of a Novel Substance P (NK1) Receptor Antagonist in Major Depression

Kramer, M. S., Winokur, A., Kelsey, J., Preskorn, S. H., Rothschild, A. J., Snavely, D., Ghosh, K., Ball, W. A., Reines, S. A., Munjack, D., et al. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300260 · Cited by 256

Low baseline and yohimbine-stimulated plasma neuropeptide Y (NPY) levels in combat-related PTSD

Rasmusson, A. M., Hauger, R. L., Morgan, C. A., Bremner, J. D., Charney, D. S., & Southwick, S. M. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00185-7 · Cited by 250

Important role of hypothalamic Y2 receptors in body weight regulation revealed in conditional knockout mice

Sainsbury, A., Schwarzer, C., Couzens, M., Fetissov, S., Furtinger, S., Jenkins, A., Cox, H. M., Sperk, G., Hökfelt, T., & Herzog, H. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.132043299 · Cited by 246

Life without neuropeptide Y.

Palmiter, R. D., Erickson, J. C., Hollopeter, G., Baraban, S. C., & Schwartz, M. W. (1998) · PubMed · Cited by 242

Characterization of (2 S,4 R)-1-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a Selective and Orally Active Vasopressin V1b Receptor Antagonist

Gal, C. S.-L., Wagnon, J., Simiand, J., Griebel, G., Lacour, C., Guillon, G., Barberis, C., Brossard, G., Soubrié, P., Nisato, D., et al. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.3.1122 · Cited by 211

The Neuropeptide Y (NPY) Y1 Receptor Subtype Mediates NPY-induced Antidepressant-like Activity in the Mouse Forced Swimming Test

Redrobe, J. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00403-1 · Cited by 207

Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents

Perrault, G., Griebel, G., & Sanger, D. J. (1998) · Psychopharmacology · doi:10.1007/s002130050645 · Cited by 207

Galanin GAL-R1 Receptor Null Mutant Mice Display Increased Anxiety-Like Behavior Specific to the Elevated Plus-Maze

Holmes, A., Kinney, J. W., Wrenn, C. C., Li, Q., Yang, R. J., Ma, L., Vishwanath, J., Saavedra, M. C., Innerfield, C. E., Jacoby, A. S., et al. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300164 · Cited by 202

Effects of transgenic overproduction of CRH on anxiety‐like behaviour

Van Gaalen, M. M., Stenzel‐Poore, M. P., Holsboer, F., & Steckler, T. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.02040.x · Cited by 189

Reduced anxiety and improved stress coping ability in mice lacking NPY‐Y2 receptors

Tschenett, A., Singewald, N., Carli, M., Balducci, C., Salchner, P., Vezzani, A., Herzog, H., & Sperk, G. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02725.x · Cited by 180

Corticotropin Releasing Hormone Type 2 Receptors in the Dorsal Raphe Nucleus Mediate the Behavioral Consequences of Uncontrollable Stress

Hammack, S. E., Schmid, M. J., LoPresti, M. L., Der-Avakian, A., Pellymounter, M. A., Foster, A. C., Watkins, L. R., & Maier, S. F. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-03-01019.2003 · Cited by 176

Alterations in arginine vasopressin neurons in the suprachiasmatic nucleus in depression

Zhou, J.-N., Riemersma, R. F., Unmehopa, U. A., Hoogendijk, W. J. G., van Heerikhuize, J. J., Hofman, M. A., & Swaab, D. F. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.7.655 · Cited by 172

Is There a Future for Neuropeptide Receptor Ligands in the Treatment of Anxiety Disorders?

Griebel, G. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00041-2 · Cited by 171

Reduction of Hypothalamic Vasopressinergic Hyperdrive Contributes to Clinically Relevant Behavioral and Neuroendocrine Effects of Chronic Paroxetine Treatment in a Psychopathological Rat Model

Keck, M. E., Welt, T., Müller, M. B., Uhr, M., Ohl, F., Wigger, A., Toschi, N., Holsboer, F., & Landgraf, R. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300040 · Cited by 168

Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice

Teixeira, R. M., Santos, A. R. S., Ribeiro, S. J., Calixto, J. B., Rae, G. A., & De Lima, T. C. M. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(96)00390-1 · Cited by 166

Voluntary Alcohol Consumption Is Controlled via the Neuropeptide Y Y1 Receptor

Thiele, T. E., Koh, M. T., & Pedrazzini, T. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-03-j0006.2002 · Cited by 158

Receptor Binding, Behavioral, and Electrophysiological Profiles of Nonpeptide Corticotropin-Releasing Factor Subtype 1 Receptor Antagonists CRA1000 and CRA1001

Okuyama, S., Chaki, S., Kawashima, N., Suzuki, Y., Ogawa, S., Nakazato, A., Kumagai, T., Okubo, T., & Tomisawa, K. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38220-5 · Cited by 154

Comparison of the phenotype of NK1R−/− mice with pharmacological blockade of the substance P (NK 1 ) receptor in assays for antidepressant and anxiolytic drugs

Rupniak, N. M. J., Carlson, E. J., Webb, J. K., Harrison, T., Porsolt, R. D., Roux, S., Felipe, C. D., Hunt, S. P., Oates, B. D., & Wheeldon, A. (2001) · Behavioural Pharmacology · doi:10.1097/00008877-200111000-00011 · Cited by 151

Brain Penetrance, Receptor Occupancy and Antistress In Vivo Efficacy of a Small Molecule Corticotropin Releasing Factor Type I Receptor Selective Antagonist

Heinrichs, S. C., Souza, E. B. D., Schulteis, G., Lapsansky, J. L., & Grigoriadis, D. E. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00299-3 · Cited by 151

Distribution of galaninergic immunoreactivity in the brain of the mouse

Pérez, S. E., Wynick, D., Steiner, R. A., & Mufson, E. J. (2001) · The Journal of Comparative Neurology · doi:10.1002/cne.1171 · Cited by 147

Neuropeptide Y (NPY) and depression: From animal studies to the human condition

Redrobe, J. P., Dumont, Y., & Quirion, R. (2002) · Life Sciences · doi:10.1016/s0024-3205(02)02159-8 · Cited by 146

Neuropeptide Y receptor subtypes in the basolateral nucleus of the amygdala modulate anxiogenic responses in rats

Sajdyk, T. J., Schober, D. A., & Gehlert, D. R. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(02)00234-4 · Cited by 141

5-Hydroxytryptamine (5-HT)1A Autoreceptor Adaptive Changes in Substance P (Neurokinin 1) Receptor Knock-Out Mice Mimic Antidepressant-Induced Desensitization

Froger, N., Gardier, A. M., Moratalla, R., Alberti, I., Léna, I., Boni, C., Felipe, C. D., Rupniak, N. M. J., Hunt, S. P., Jacquot, C., et al. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-20-08188.2001 · Cited by 140

Anticonvulsant activity of a nonpeptide galanin receptor agonist

Saar, K., Mazarati, A. M., Mahlapuu, R., Hallnemo, G., Soomets, U., Kilk, K., Hellberg, S., Pooga, M., Tolf, B., Shi, T.-J. S., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.102163499 · Cited by 129

Evaluation of an Anxiety-Related Phenotype in Galanin Overexpressing Transgenic Mice

Holmes, A., Yang, R. J., & Crawley, J. N. (2002) · Journal of Molecular Neuroscience · doi:10.1385/jmn:18:1-2:151 · Cited by 126

Role of VIP, PACAP, and related peptides in the regulation of the hypothalamo—pituitary–adrenal axis

Nussdorfer, G. G., & Malendowicz, L. K. (1998) · Peptides · doi:10.1016/s0196-9781(98)00102-8 · Cited by 125

Neuropeptide Y-Y2 receptors mediate anxiety in the amygdala

Sajdyk, T. J., Schober, D. A., Smiley, D. L., & Gehlert, D. R. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(01)00679-7 · Cited by 123

The Gerbil Elevated Plus-maze II Anxiolytic-like Effects of Selective Neurokinin NK1 Receptor Antagonists

Varty, G. B. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00313-5 · Cited by 119

Anxiolytic-like action of centrally administered galanin

Bing, O., Møller, C. H., Engel, J. A., Söderpalm, B., & Heilig, M. A. (1993) · Neuroscience Letters · doi:10.1016/0304-3940(93)90846-d · Cited by 114

Brain Neuropeptide Υ (NPY) in Stress and Alcohol Dependence

Heilig, M. A., & Thorsell, A. (2002) · Reviews in the Neurosciences · doi:10.1515/revneuro.2002.13.1.85 · Cited by 113

Anxiogenic-Like Action of Galanin after Intra-Amygdala Administration in the Rat

Möller, C., Sommer, W., Thorsell, A., & Heilig, M. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00102-x · Cited by 112

Colocalization of Peptide and Glucocorticoid Receptor Immunoreactivities in Rat Central Amygdaloid Nucleus

Honkaniemi, J., Pelto-Huikko, M., Rechardt, L., Isola, J., Lammi, A., Fuxe, K., Gustafsson, J.-Å., Wikström, A.-C., & Hökfelt, T. (2008) · Neuroendocrinology · doi:10.1159/000126156 · Cited by 103

The Corticotropin-Releasing Factor1 Receptor Antagonist R121919 Attenuates the Behavioral and Endocrine Responses to Stress

Gutman, D. A., Owens, M. J., Skelton, K. H., Thrivikraman, K. V., & Nemeroff, C. B. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.042788 · Cited by 100

Serotonin and substance P co-exist in dorsal raphe neurons of the human brain

Sergeyev, V., Hökfelt, T. G. M., & Hurd, Y. L. (1999) · Neuroreport · doi:10.1097/00001756-199912160-00044 · Cited by 96

Genomic screen for QTLs underlying alcohol consumption in the P and NP rat lines

Bice, P. J., Foroud, T., Bo, R., & Castelluccio, P. (1998) · Mammalian Genome · doi:10.1007/s003359900905 · Cited by 94

Pharmacological evidence supporting a role for galanin in cognition and affect

Wrenn, C. C., & Crawley, J. N. (2001) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(00)00156-1 · Cited by 94

Selective Blockade of Neurokinin-2 Receptors Produces Antidepressant-Like Effects Associated with Reduced Corticotropin-Releasing Factor Function

Steinberg, R., Alonso, R., Griebel, G., Bert, L., Jung, M., Oury-Donat, F., Poncelet, M., Gueudet, C., Desvignes, C., Fur, G. L., et al. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29250-8 · Cited by 94

Regulation of pituitary corticotropin releasing hormone receptors

Aguilera, G., Rabadan‐Diehl, C., & Nikodémová, M. (2001) · Peptides · doi:10.1016/s0196-9781(01)00390-4 · Cited by 91

Galanin Is a Potent In Vivo Modulator of Mesencephalic Serotonergic Neurotransmission

Kehr, J. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00309-3 · Cited by 91

Substance P induces a cardiovascular defense reaction in the rat: pharmacological characterization.

Unger, T., Carolus, S. M., Demmert, G., et al. (1988) · Circulation Research · doi:10.1161/01.res.63.4.812 · Cited by 90

Blockade of central neuropeptide Y (NPY) Y2 receptors reduces ethanol self-administration in rats

Thorsell, A., Rimondini, R., & Heilig, M. A. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00904-7 · Cited by 89

Stress-induced expression of co-localized neuropeptides in hypothalamic and amygdaloid neurons

Palkovits, M. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00549-5 · Cited by 84

Impulse flow dependency of galanin release in vivo in the rat ventral hippocampus.

Consolo, S., Baldi, G., Russi, G., Civenni, G., Bartfai, T., & Vezzani, A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.17.8047 · Cited by 82

The NK1-receptor antagonist NKP608 has an antidepressant-like effect in the chronic mild stress model of depression in rats

Papp, M., Vassout, A., & Gentsch, C. (2000) · Behavioural Brain Research · doi:10.1016/s0166-4328(00)00230-8 · Cited by 82

Substance P (Neurokinin 1) Receptor Antagonists Enhance Dorsal Raphe Neuronal Activity

Conley, R. K., Cumberbatch, M. J., Mason, G. S., Williamson, D. J., Harrison, T., Locker, K. L., Swain, C. J., Maubach, K. A., O’Donnell, R., Rigby, M., et al. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-17-07730.2002 · Cited by 81

Substance P is involved in the sensitization of the acoustic startle response by footshocks in rats

Krase, W., Koch, M., & Schnitzler, H. (1994) · Behavioural Brain Research · doi:10.1016/0166-4328(94)90053-1 · Cited by 79

Anxiolytic actions of the substance P (NK1) receptor antagonist L-760735 and the 5-HT1A agonist 8-OH-DPAT in the social interaction test in gerbils

Cheeta, S., Tucci, S. A., Sandhu, J., Williams, A. R., Rupniak, N. M. J., & File, S. E. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02846-3 · Cited by 78

4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1 S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine Hydrochloride (SSR125543A): A Potent and Selective Corticotrophin-Releasing Factor1 Receptor Antagonist. I. Biochemical and Pharmacological Characterization

Gully, D., Geslin, M., Serva, L., Fontaine, E., Roger, P., Lair, C., Darre, V., MARCY, C. H., Rouby, P.-E., Simiand, J., et al. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.1.322 · Cited by 78

Neurotransmitters and Neuromodulators

Halbach, O. V. B. U., & Dermietzel, R. (2006) · Wiley eBooks · doi:10.1002/9783527609963 · Cited by 78

Interactions of norepinephrine and galanin in the central amygdala and lateral bed nucleus of the stria terminalis modulate the behavioral response to acute stress

Morilak, D. A., Cecchi, M., & Khoshbouei, H. (2003) · Life Sciences · doi:10.1016/s0024-3205(03)00392-8 · Cited by 77

Neurotransmitters and neuromodulators : handbook of receptors and biological effects

Halbach, O. V. B. U., Dermietzel, R., & Ballantyne, D. (2002) · Wiley-VCH eBooks · Cited by 75

Chronic substance P (NK1) receptor antagonist and conventional antidepressant treatment increases burst firing of monoamine neurones in the locus coeruleus

Maubach, K. A., Martin, K., Chicchi, G. G., Harrison, T., Wheeldon, A., Swain, C. J., Cumberbatch, M. J., Rupniak, N. M. J., & Seabrook, G. R. (2002) · Neuroscience · doi:10.1016/s0306-4522(01)00467-5 · Cited by 72

Desmopressin Normalizes the Blunted Adrenocorticotropin Response to Corticotropin-Releasing Hormone in Melancholic Depression: Evidence of Enhanced Vasopressinergic Responsivity

Dinan, T. G., Lavelle, E., Scott, L. V., Newell-Price, J. D. C., Medbak, S., & Grossman, A. B. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.6.5723 · Cited by 69

2,3-Dihydro-dithiin and -dithiepine-1,1,4,4-tetroxides: small molecule non-peptide antagonists of the human galanin hGAL-1 receptor

Scott, M. K., Ross, T. M., Lee, D. H. S., Wang, H.-Y., Shank, R. P., Wild, K. D., Davis, C. B., Crooke, J. J., Potocki, A. C., & Reitz, A. B. (2000) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(00)00062-6 · Cited by 66

Anxiolytics: past, present, and future agents.

Nemeroff, C. B. (2003) · PubMed · Cited by 64

Differential galanin receptor‐1 and galanin expression by 5‐HT neurons in dorsal raphé nucleus of rat and mouse: evidence for species‐dependent modulation of serotonin transmission

Larm, J. A., Shen, P., & Gundlach, A. L. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02471.x · Cited by 60

Galanin attenuates basal and antidepressant drug-induced increase of extracellular serotonin and noradrenaline levels in the rat hippocampus

Yoshitake, T., Reenilä, I., Ögren, S. O., Hökfelt, T. G. M., & Kehr, J. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(03)00020-x · Cited by 56

Electrophysiologic Effects of Galanin on Neurons of the Central Nervous System a

Pieribone, V. A., Xu, Q., ZHANG, X., & Hökfelt, T. G. M. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb10701.x · Cited by 33

Dose Response of Arginine Vasopressin to the CCK-B Agonist Pentagastrin

Abelson, J. L., Mellédo, J. L., & Bichet, D. G. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00182-2 · Cited by 30

Mice overexpressing CRH show reduced responsiveness in plasma corticosterone after a 5‐HT1A receptor challenge

van Gaalen, M. M., Reul, J., Gesing, A., Stenzel‐Poore, M. P., Holsboer, F., & Steckler, T. (2002) · Genes Brain & Behavior · doi:10.1034/j.1601-183x.2002.10305.x · Cited by 24

CRF2 receptors: An emerging role in anxiety

Takahashi, L. K. (2002) · Drug News & Perspectives · doi:10.1358/dnp.2002.15.2.668333 · Cited by 12

New approaches to antidepressant drug discovery: beyond monoamines

Berton, O., & Nestler, E. J. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1846 · Cited by 1,589

The ascent of mouse: advances in modelling human depression and anxiety

Cryan, J. F., & Holmes, A. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1825 · Cited by 1,198

Dynamic DNA methylation programs persistent adverse effects of early-life stress

Murgatroyd, C., Patchev, A. V., Wu, Y., Micale, V., Bockmühl, Y., Fischer, D., Holsboer, F., Wotjak, C. T., Almeida, O. F. X., & Spengler, D. (2009) · Nature Neuroscience · doi:10.1038/nn.2436 · Cited by 1,162

Neuroendocrinology of coping styles: Towards understanding the biology of individual variation

Koolhaas, J. M., de Boer, S. F., Coppens, C. M., & Buwalda, B. (2010) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2010.04.001 · Cited by 885

Metabotropic glutamate receptors as novel targets for anxiety and stress disorders

Swanson, C. J., Bures, M., Johnson, M. P., Linden, A.-M., Monn, J. A., & Schoepp, D. D. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1630 · Cited by 607